Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Atherosclerosis Reports
Erschienen in: Current Atherosclerosis Reports 5/2016

01.05.2016 | Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)

Obesity and Cardiovascular Disease: a Risk Factor or a Risk Marker?

verfasst von: Taher Mandviwala, Umair Khalid, Anita Deswal

Erschienen in: Current Atherosclerosis Reports | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

In the USA, 69 % of adults are either overweight or obese and 35 % are obese. Obesity is associated with an increased incidence of various cardiovascular disorders. Obesity is a risk marker for cardiovascular disease, in that it is associated with a much higher prevalence of comorbidities such as diabetes, hypertension, and metabolic syndrome, which then increase the risk for cardiovascular disease. However, in addition, obesity may also be an independent risk factor for the development of cardiovascular disease. Furthermore, although obesity has been shown to be an independent risk factor for several cardiovascular diseases, it is often associated with improved survival once the diagnosis of the cardiovascular disease has been made, leading to the term “obesity paradox.” Several pathways linking obesity and cardiovascular disease have been described. In this review, we attempt to summarize the complex relationship between obesity and cardiovascular disorders, in particular coronary atherosclerosis, heart failure, and atrial fibrillation.
Literatur
1.
Flegal K, Carroll M, Kit B, Ogden C. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307:491–7.CrossRefPubMed
2.
Fontaine K, Redden D, Wang C, Westfall A, Allison D. Years of life lost due to obesity. JAMA. 2003;289:187–93.CrossRefPubMed
3.
Poirier P, Giles T, Bray G, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation. 2006;113:898–918.CrossRefPubMed
4.
Poirier P, Martin J, Marceau P, Biron S, Marceau S. Impact of bariatric surgery on cardiac structure, function and clinical manifestations in morbid obesity. Expert Rev Cardiovasc Ther. 2004;2:193–201.CrossRefPubMed
5.
Horwich TB, Fonarow GC, Hamilton M, MacLellan W, Woo M, Tillisch J. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38:789–95.CrossRefPubMed
6.•
Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1(2):93–102. Lavie et al. review the data on obesity and cardiopulmonary fitness in heart failure patients. The article also includes informative data on obesity and its impact on treatments such as heart transplantation and LV assist devices.CrossRefPubMed
7.
Shah R, Gayat E, Januzzi Jr JL, et al. Mebazaa A Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. J Am Coll Cardiol. 2014;63:778–85.CrossRefPubMed
8.
9.
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report: National Institutes of Health. Obes Res. 1998;2:51S–209S.
10.
Kurpad SS, Tandon H, Srinivasan K. Waist circumference correlates better with body mass index than waist-to-hip ratio in Asian Indians. Natl Med J India. 2003;16(4):189–92.PubMed
11.•
Rocha V, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6:399–409. Rocha et al. review in detail the interplay between obesity and inflammation leading to the development of atherosclerosis.CrossRefPubMed
12.
13.
Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289:1799–804.CrossRefPubMed
14.
Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–80.CrossRefPubMed
15.
Ridker P. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129–38.CrossRefPubMed
16.
Everett B, Kurth T, Buring J, Ridker P. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol. 2006;48:2235–42.CrossRefPubMedPubMedCentral
17.
Ridker P, Stampfer M, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285(19):2481–5.CrossRefPubMed
18.
Pradhan A, Manson J, Rifai N, Buring J, Ridker P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–34.CrossRefPubMed
19.
Visser M, Bouter L, McQuillan G, Wener M, Harris T. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.CrossRefPubMed
20.
Pearson T, Mensah G, Alexander R, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.CrossRefPubMed
21.
Ridker P, Rifai N, Pfeffer M, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CAre) investigators. Circulation. 1998;98:839–44.CrossRefPubMed
22.
Ridker P, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–65.CrossRefPubMed
23.
Ridker P, Danielson E, Fonseca F, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.CrossRefPubMed
24.
Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity and diet-induced insulin resistance with salicylates or targeted disruption of ikkbeta. Science. 2001;293:1673–7.CrossRefPubMed
25.
Fleischman A, Shoelson S, Bernier R, Goldfine A. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31:289–94.CrossRefPubMedPubMedCentral
26.
Koska J, Ortega E, Bunt J, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia. 2009;52:385–93.CrossRefPubMedPubMedCentral
27.
Wolk R, Berger P, Lennon J, Brilakis E, Somers V. Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation. 2003;108:2206–11.CrossRefPubMed
28.
McGill H, McMahan C, Herderick E, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002;105:2712–8.CrossRefPubMed
29.
Rabkin S, Mathewson F, Hsu P. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol. 1977;39:452–8.CrossRefPubMed
30.
Manson J, Colditz G, Stampfer M, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322:882–9.CrossRefPubMed
31.
Wilson P, D’Agostino R, Sullivan L, Parise H, Kannel W. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;16:1867–72.CrossRef
32.
Din-Dzietham R, Liu Y, Bielo M, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation. 2007;116(13):1488–96.CrossRefPubMed
33.
Lau D, Dhillon B, Yan H, Szmitko P, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005;288:2031–41.CrossRef
34.
Juge-Aubry C, Henrichot E, Meier C. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab. 2005;19:547–66.CrossRefPubMed
35.
Knudson J, Dincer U, Zhang C, et al. Leptin receptors are expressed in coronary arteries and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2005;289:48–56.CrossRef
36.
Trayhurn P, Wood I. Signaling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans. 2005;33:1078–81.CrossRefPubMed
37.
Payne G, Kohr M, Tune J. Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease. Br J Pharmacol. 2012;165(3):659–69.CrossRefPubMedPubMedCentral
38.
Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis. 2009;19:440–9.CrossRefPubMed
39.
Salama M, Morad A, Saleh M, Sabri N, Zaki M, ElSafady L. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. J Clin Pharm Ther. 2012;37:630–6.CrossRefPubMed
40.
Kragelund C, Hassager C, Hildebrandt P, Torp-Pedersen C, Kober L. Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol. 2005;98:123–31.CrossRefPubMed
41.
Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.CrossRefPubMed
42.
Madala M, Franklin B, Chen A, et al. Obesity and age of first non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008;52:979–85.CrossRefPubMed
43.
Das S, Alexander K, Chen A, et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data). J Am Coll Cardiol. 2011;58(25):2642–50.CrossRefPubMedPubMedCentral
44.
Bajaj S, Shamoon F, Gupta N, et al. Acute ST-segment elevation myocardial infarction in young adults: who is at risk? Coron Artery Dis. 2011;22:238–44.CrossRefPubMed
45.
Jamil G, Jamil M, Alkhazraji H, et al. Risk factor assessment of young patients with acute myocardial infarction. Am J Cardiovasc Dis. 2013;3:170–4.PubMedPubMedCentral
46.
Lavie C, Milani R, Ventura H. Obesity and cardiovascular disease: risk factor, paradox and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925–32.CrossRefPubMed
47.
Nikolsky E, Kosinski E, Mishkel GJ, et al. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). Am J Cardiol. 2005;95:709–15.CrossRefPubMed
48.
Sarno G, Garg S, Onuma Y, et al. The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with biolimus- and sirolimus-eluting stents (from the LEADERS Trial). Am J Cardiol. 2010;105:475–9.CrossRefPubMed
49.
Sarno G, Raber L, Onuma Y, et al. Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents. Am J Cardiol. 2011;108:195–201.CrossRefPubMed
50.
Akin I, Tolg R, Hochadel M, et al. No evidence of “obesity paradox” after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry. JACC Cardivasc Interv. 2012;5(2):162–9.CrossRef
51.
Wang Z, Zhou Y, Zhao Y, et al. Effect of obesity on repeat revascularization in patients undergoing percutaneous coronary intervention with drug-eluting stents. Obesity (Silver Spring). 2012;20:141–6.CrossRef
52.
Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol. 2007;120:188–92.CrossRefPubMed
53.
Mahaffey K, Tonev S, Spinler S, et al. Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol. 2010;139:123–33.CrossRefPubMed
54.
Kadakia M, Fox C, Scirica B, Murphy S, Bonaca M, Morrow D. Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. Heart. 2011;97:1782–7.CrossRefPubMedPubMedCentral
55.
Oreopoulos A, Padwal R, Norris C, Mullen J, Pretorius V, Kalantar-Zadeh K. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. Obesity (Silver Spring). 2008;16:442–50.CrossRef
56.
Li Y, Lin G, Lin C, Wang J, Han C. Relation of body mass index to mortality among patients with percutaneous coronary intervention longer than 5 years follow-up: a meta-analysis. Int J Cardiol. 2013;168:4315–8.CrossRefPubMed
57.
58.
59.
Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70(9):921–4.CrossRefPubMed
60.
Kenchaiah S, Evans J, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13.CrossRefPubMed
61.
Kenchaiah S, Sesso H, Gaziano J. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation. 2009;119(1):44–52.CrossRefPubMedPubMedCentral
62.
Loehr L, Rosamond W, Poole C, et al. Association of multiple anthropometrics of overweight and obesity with incident heart failure: the Atherosclerosis Risk in Communities study. Circ Heart Fail. 2009;2(1):18–24.CrossRefPubMedPubMedCentral
63.
Hu G, Jousilahti P, Antikainen R, Katzmarzyk PT, Tuomilehto J. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121(2):237–44.CrossRefPubMed
64.
Hu G, Jousilahti P, Antikainen R, Katzmarzyk P, Tuomilehto J. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121:237–44.CrossRefPubMed
65.
Pascual M, Pascual D, Soria F, et al. Effects of isolated obesity on systolic and diastolic left ventricular function. Heart. 2003;89(10):1152–6.CrossRefPubMedPubMedCentral
66.
Alpert M, Alexander J. Obesity and ventricular function in man: systolic function. In: Alpert MA, Alexander JK, editors. The heart and lung in obesity. Armonk, New York: Futura Publishing Company; 1998. p. 77–94.
67.
Alexander J, Dennis E, Smith W, Amad K, Duncan W, Austin R. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull. 1962;1:39–44.PubMed
68.
Alpert M, Lambert C, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol. 1995;76:1194–7.CrossRefPubMed
69.
Nakajima T, Fujioka S, Tokunaga K, Hirobe K, Matsuzawa Y, Tarui S. Noninvasive study of left ventricular performance in obese patients: influence of duration of obesity. Circulation. 1985;71:481–6.CrossRefPubMed
70.
McGavock J, Victor R, Unger R, Szczepaniak L. Adiposity of the heart, revisited. Ann Intern Med. 2006;144:517–24.CrossRefPubMed
71.
Poirier P, Giles T, Bray G, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968–76.CrossRefPubMed
72.
Kapoor J, Heidenreich P. Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship. Am Heart J. 2010;159:75–80.CrossRefPubMed
73.
Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998–1005.CrossRefPubMedPubMedCentral
74.
Ingelsson E, Sundstrom J, Arnlöv J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294(3):334–41.CrossRefPubMed
75.
Wannamethee S, Shaper A, Whincup P, Lennon L, Sattar N. Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role? J Am Coll Cardiol. 2011;58:1870–7.CrossRefPubMed
76.
Frankel D, Vasan R, D’Agostino R, et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol. 2009;53(9):754–62.CrossRefPubMedPubMedCentral
77.
Bahrami H, Bluemke D, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008;51(18):1775–83.CrossRefPubMed
78.
Bozkurt B, Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J. 2005;150(6):1233–9.CrossRefPubMed
79.
Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756–62.CrossRefPubMed
80.•
Khalid U, Ather S, Bavishi C, et al. Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol. 2014;64(25):2743–9. This is the first study that describes the obesity paradox in heart failure, based on pre-heart failure (i.e. premorbid) BMI. The authors found that obesity and underweight compared to normal weight prior to the development of heart failure was associated with improved survival after the development of heart failure.CrossRefPubMedPubMedCentral
81.
Lavie C, Ventura H. Weighing in on obesity and the obesity paradox in heart failure. J Card Fail. 2011;17:381–3.CrossRefPubMed
82.
Blogowski W, Serwin K, Budkowska M, et al. Clinical analysis of systemic and adipose tissue levels of selected hormones/adipokines and stromal-derived factor-1. J Biol Regul Homeost Agents. 2012;26:607–15.PubMed
83.
Vest A, Wu Y, Hachamovitch R, Young J, Cho L. The heart failure overweight/obesity survival paradox: the missing sex link. J Am Coll Cardiol HF. 2015;3:917–26.
84.
Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:147–239.CrossRef
85.
Wang T, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471–7.CrossRefPubMed
86.
Frost L, Benjamin E, Fenger-Grøn M, Pedersen A. Tjønneland A, Overvad K. Body fat, body fat distribution, lean body mass, and atrial fibrillation and flutter. A Danish cohort study. Obesity (Silver Spring). 2014;22:1546–52.CrossRef
87.
Wanahita N, Messerli F, Bangalore S, Gami A, Somers V, Steinberg J. Atrial fibrillation and obesity: results of a meta-analysis. Am Heart J. 2008;155:310–5.CrossRefPubMed
88.
Iacobellis G, Ribaudo M, Leto G, et al. Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity. Obes Res. 2002;10:767–73.CrossRefPubMed
89.
Gottdiener J, Reda D, Williams D, Materson B. Left atrial size in hypertensive men: influence of obesity, race and age. J Am Coll Cardiol. 1997;29:651–8.CrossRefPubMed
90.•
Goudis C, Korantzopoulos P, Ntalas I, Kallergis E, Ketikoglou D. Obesity and atrial fibrillation: a comprehensive review of the pathophysiological mechanisms and links. J Cardiol. 2015;66(5):361–9. Goudis et al. review the most recent clinical and experimental studies linking obesity to atrial fibrillation.CrossRefPubMed
91.
Yang W, Xu L, Zhang H. Association of CETP and CRP gene polymorphisms with non-valvular atrial fibrillation in Chinese Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008;25:225–229.
92.
Kang Y, Hu Y, Li N. Advances in research on G protein-coupled inward rectifier K(+) channel gene. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2012;34:426–430.
93.
Rabkin S. The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis. Metab Syndr Relat Disord. 2014;12:31–42.CrossRefPubMed
94.
Thanassoulis G, Massaro J, O’Donnell CJ, et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm E. 2010;3(4):345–50.CrossRef
95.
Al Chekakie M, Welles C, Metoyer R, et al. Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol. 2010;56:784–8.CrossRefPubMed
96.
Wong C, Abed H, Molaee P, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol. 2011;57(17):1745–51.CrossRefPubMed
97.
Shin S, Yong H, Lim H, et al. Total and interatrial epicardial adipose tissues are independently associated with left atrial remodeling in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(6):647–55.CrossRefPubMed
98.
Hatem S, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res. 2014;102:205–13.CrossRefPubMed
99.
Guo Y, Lip G, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60:2263–70.CrossRefPubMed
100.
Mahajan R, Brooks A, Shipp N. Epicardial fat infiltration of atrial musculature creates the substrate for atrial fibrillation in obesity. Heart Rhythm. 2012;9:124.
101.
102.
Pathak R, Middeldorp M, Meredith M, Mehta A, MActSt, Mahajan R, Wong C, Twomey D, Elliott A, Kalman J, Abhayaratna W, Lau D, Sanders P. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015;65:2159–2169
Metadaten
Titel
Obesity and Cardiovascular Disease: a Risk Factor or a Risk Marker?
verfasst von
Taher Mandviwala
Umair Khalid
Anita Deswal
Publikationsdatum
01.05.2016
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports / Ausgabe 5/2016
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-016-0575-4

Weitere Artikel der Ausgabe 5/2016

Current Atherosclerosis Reports 5/2016 Zur Ausgabe

Nonstatin Drugs (E. deGoma, Section Editor)

Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia

Cardiovascular Disease and Stroke (S. Prabhakaran, Section Editor)

Approach to Statin Use in 2016: an Update

Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)

An Update on Gender Disparities in Coronary Heart Disease Care

Cardiovascular Disease and Stroke (S. Prabhakaran, Section Editor)

Transcatheter Aortic Valve Implantation

Genetics (A. Marian, Section Editor)

Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?

Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)

Cardiorespiratory Fitness and Atherosclerosis: Recent Data and Future Directions

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise